Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
64.27
+0.19 (+0.30%)
Official Closing Price
Updated: 4:15 PM EDT, May 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines
September 22, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Completes Acquisition of MiroBio
September 20, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
September 16, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19
September 16, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline
September 15, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity
September 13, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study
September 07, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Kite’s CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
September 06, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy® Regardless of Their HER2 Status
September 04, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
August 29, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022
August 29, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option
August 22, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care
August 17, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead to Acquire Remaining Worldwide Rights of Trodelvy®
August 15, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study
August 15, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency
August 09, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Acquire MiroBio
August 04, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces Second Quarter 2022 Financial Results
August 02, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Biktarvy® Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those With HBV Coinfection
July 28, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Kite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
July 22, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
CHMP Adopts Positive Opinion Recommending Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19
July 22, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic
July 21, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity
July 20, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)
July 19, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
July 12, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Is Merck & Co. Inc. (NYSE: MRK) a Great Long-Term Dividend Pick?
July 12, 2022
When you're on the hunt for a great long-term dividend stock, you may want the perfect stock. The Dividend Aristocrats or Dividend Kings may come to mind first — companies that have proven they offer a...
Via
MarketBeat
Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel
July 12, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Liposome Drug Delivery Market Size, Share, Key Players Analysis, Growth Factors, New Technology, Application and Regional Forecast to 2028
July 08, 2022
Global Liposome Drug Delivery Market Size was estimated at USD 3316.64 million in 2021 and is projected to reach USD 7768.01 million by 2028, exhibiting a CAGR of 12.93% during the forecast period
Via
SBWire
Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma
June 28, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
June 27, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.